08/31/2026
JUST IN: Scientists have identified a key role for the cannabinoid receptor CB2R in limiting the spread of breast cancer. In experiments using three-dimensional organoids derived from human patient samples and mouse models of mammary tumors, a brief four-day exposure to an ultra-low dose of the cannabis compound THC triggered lasting changes in cancer cell behavior.
Treated organoids displayed markedly lower invasiveness, reduced self-renewal capacity, and diminished ability to initiate new tumors. These effects appeared to operate primarily through CB2R rather than the psychoactive CB1R.
Surprisingly, both an agonist that activates CB2R and an inverse agonist that lowers its baseline activity produced similar anti-cancer outcomes, while organoids lacking the receptor still underwent comparable shifts, pointing to the importance of carefully tuned receptor signaling in controlling cellular plasticity.
The reprogramming proved durable. When THC-exposed organoids were transplanted into cancer-prone mice, tumors formed more slowly, grew less aggressively, and generated fewer metastatic lesions in the lungs. The differentiated state also increased estrogen receptor activity, rendering the cells more sensitive to the endocrine therapy tamoxifen.
By locking cancer cells into a less stem-like, luminal identity through transient chromatin remodeling, CB2R modulation may occupy resources that would otherwise fuel tumor expansion and metastasis. These findings open promising avenues for differentiation-based strategies that complement conventional treatments and constrain the adaptive flexibility of breast cancer cells.
Source: Martínez-Illescas et al., Communications Biology (2026), DOI 10.1038/s42003-026-10837-1
